It's time for the IN VIVO Blog's Fourth Annual Deal of the Year! competition. This year we're once again presenting awards in t...

It really is a mad, mad, mad, mad world. Libya . Yemen . Japan . The relentless worrisome news is enough to drive this blogger to the madnes...

In what could almost be categorized as the silver lining in an otherwise black cloud for Basilea, the FDA has issued a warning letter to J...

Heave a sigh of relief, Big Pharma. Co-promotes are on the way out. At least, according to Ben Bonifant, VP at consultants Campbell Alliance...

So Synta’s PR firm were pushing today’s deal with GlaxoSmithKline at us as “one of the biggest product deals this year” and indeed “among t...

You could see it coming. Well, kind of. Idenix on Friday snuck out the news that it was bailing out of its US and European co-promote with N...

When Merck and partner Neuromed yesterday pulled the plug on Phase II chronic pain treatment NMED-160/MK-6721 , another co-promote bit the ...

Sales force size, that is. ZymoGenetics’ ex-US commercialization deal with Bayer HealthCare on lead recombinant human thrombin didn’t come a...